Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 13/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833211 | 0.86 | ITGB1 (0.50) | FPR2ITGB1ITGA4ITGB7ALDH1A1 | |
| SCHEMBL1021636 | 0.85 | ITGA4 (0.48) | FPR2ITGB1ITGA4ITGB7 | |
| SCHEMBL2991512 | 0.80 | SLC7A5 (0.54) | LDHA | |
| SCHEMBL7271174 | 0.78 | SIGMAR1 (0.56) | FPR2 | |
| SCHEMBL839840 | 0.78 | SIGMAR1 (0.56) | FPR2 | |
| SCHEMBL1958454 | 0.78 | SIGMAR1 (0.56) | FPR2 | |
| SCHEMBL3833206 | 0.77 | ALDH1A1 (0.51) | ITGB1ITGA4ITGB7ALDH1A1LDHA | |
| SCHEMBL25424592 | 0.77 | MME (0.61) | — | |
| SCHEMBL25424588 | 0.77 | MME (0.61) | — | |
| Hydrochloric Acid SCHEMBL393424 | 0.77 | SIGMAR1 (0.55) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | FPR2 33/4885ITGB1 3/4885ITGA4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.